Determination of the most appropriate method for extrapolating overall survival data from a placebo-controlled clinical trial of lenvatinib for progressive, radioiodine-refractory differentiated thyroid cancer

BACKGROUND: Cost-effectiveness models for the treatment of long-term conditions often require information on survival beyond the period of available data. OBJECTIVES: This paper aims to identify a robust and reliable method for the extrapolation of overall survival (OS) in patients with radioiodine-...

Descripción completa

Detalles Bibliográficos
Autores principales: Tremblay, Gabriel, Livings, Christopher, Crowe, Lydia, Kapetanakis, Venediktos, Briggs, Andrew
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Methodology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934460/
https://www.ncbi.nlm.nih.gov/pubmed/27418847
http://dx.doi.org/10.2147/CEOR.S107498

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4934460/
https://www.ncbi.nlm.nih.gov/pubmed/27418847
http://dx.doi.org/10.2147/CEOR.S107498

Ejemplares similares